Our story

How one cancer patient changed the world of Lyme disease forever.

A chance discovery in 1994. A Nobel Prize-winning principle. Thirty years of refinement. This is how it began.

1994 — Bad Aibling, Bavaria

The accidental discovery

Dr. Friedrich Douwes M.D. (1945–2022) did not set out to change the treatment of Lyme disease. He was trying to save a woman from cancer.

In 1991, Dr. Douwes had founded Klinik St. Georg in Bad Aibling, a small spa town nestled in the foothills of the Bavarian Alps. The clinic was built on a conviction that mainstream oncology was failing patients by treating tumors in isolation from the bodies they inhabited. He became a pioneer of whole-body hyperthermia for cancer — the controlled elevation of a patient's core body temperature to attack malignant cells that conventional therapies could not reach.

By 1994, his hyperthermia program was among the most advanced in Europe. And it was in that year that a woman arrived at his clinic with metastasized breast cancer.

Her case was serious. The tumor had spread. But something else had been destroying her life for far longer than the cancer — something that no oncologist, no neurologist, no psychiatrist had been able to name. For a decade, she had been drowning in relentless brain fog. Crushing fatigue. Cognitive collapse so severe she could barely follow a conversation. She could barely think. She could barely function. And no one could tell her why.

Dr. Douwes treated her cancer with whole-body hyperthermia, elevating her core body temperature to fight the tumor, as he had done with hundreds of patients before.

The next morning, she said the words that would redirect the trajectory of his entire career.

“Dr. Douwes, what did you do? You put the sun back in my brain. I couldn't think for ten years.”
— Cancer patient, Klinik St. Georg, 1994

Her brain fog was not from the cancer. It was not a side effect of treatment. It was not psychological.

It was chronic Lyme disease — Borrelia burgdorferi, a spirochetal infection that had been silently colonizing her nervous system for a decade, undiagnosed, untreated, steadily erasing her ability to think.

The hyperthermia, intended to fight her tumor, had simultaneously attacked the Borrelia. The heat killed the spirochetes. And after ten years of darkness, the fog lifted overnight.

1994–1996

The pattern emerges

A single case could be dismissed as coincidence. Dr. Douwes was a scientist. He did not leap to conclusions.

Six months later, a second cancer patient arrived — this time a woman with ovarian cancer — presenting with the same inexplicable cognitive symptoms. Brain fog. Fatigue. A mind that had simply stopped working clearly. At first, Dr. Douwes assumed the cognitive decline was a side effect of chemotherapy. He prescribed doxycycline, a standard antibiotic with known efficacy against Borrelia.

It was not enough.

The more he researched, the more he realized how devastatingly complex chronic Lyme disease truly was — far beyond what a simple course of antibiotics could address. The spirochetes burrowed into tissues. They formed biofilms. They hid from the immune system in ways that standard laboratory tests could not reliably detect.

But then he noticed something that could not be ignored. Across his oncology practice, multiple cancer patients with unexplained neurological symptoms were improving dramatically after hyperthermia — not because of the cancer treatment itself, but because the heat was killing something else entirely.

The question was no longer whether hyperthermia affected Borrelia. The question was why.

The science

Thermolability of spirochetes

In searching for answers, Dr. Douwes rediscovered a principle as old as one of the most controversial Nobel Prizes in medical history.

In 1927, the Austrian physician Julius Wagner-Jauregg won the Nobel Prize in Physiology or Medicine for an audacious idea: deliberately infecting neurosyphilis patients with malaria to induce high fevers. The fevers killed Treponema pallidum — the syphilis spirochete — because spirochetes, as a class of bacteria, are thermolabile. They cannot survive sustained elevated temperatures.

Wagner-Jauregg had demonstrated, nearly seventy years earlier, that heat was a weapon against spirochetal infections.

Could the same principle apply to Borrelia burgdorferi?

Dr. Douwes needed proof. Together with Prof. Egon Reisinger from the University of Graz, he funded and collaborated on a landmark in vitro study to test the hypothesis directly.

Reisinger E, Wendelin I, Gasser R, et al. "Antibiotics and increased temperature against Borrelia burgdorferi in vitro." Scandinavian Journal of Infectious Diseases. 1996;28(2):155–157. doi:10.3109/00365549609049067

The results were unambiguous:

  • Borrelia burgdorferi growth was impaired at 37°C and blocked entirely at 39–40°C
  • At 41–42°C, cell death was complete across all tested strains
  • The susceptibility of Borrelia to penicillin and ceftriaxone was increased up to 16-fold when temperature was elevated from 36°C to 38°C
  • Elevated body temperature combined with antibiotics was dramatically more effective than either intervention alone

The patient in 1994 had not experienced a miracle. She had experienced applied microbiology. The heat had exploited a fundamental physical vulnerability of the pathogen — and the science now confirmed it.

The protocol

Antibiotic Augmented Thermoeradication

With the in vitro evidence in hand, Dr. Douwes developed what would become the most advanced hyperthermia-based Lyme treatment protocol in the world: Antibiotic Augmented Thermoeradication (AAT).

The concept was elegant in its logic and rigorous in its execution. Elevate the patient's core body temperature to 41.6–41.8°C for approximately two hours under continuous medical supervision, while simultaneously administering high-dose intravenous antibiotics.

At these temperatures, the Borrelia spirochetes become thermolabile and begin to die. Their cell walls destabilize. Their biofilms weaken. Simultaneously, the antibiotics — now up to 16 times more effective at elevated temperatures — penetrate tissues, cross barriers, and reach reservoirs that antibiotics alone cannot touch at normal body temperature.

This was not alternative medicine. This was not fringe therapy. This was the application of a Nobel Prize-winning principle, confirmed by peer-reviewed research, delivered in a licensed hospital setting with ICU-grade monitoring.

It was the weaponization of physics and pharmacology against a pathogen that had evolved to evade every conventional approach.

1994–2024

Thirty years of refinement

What began with one patient's words became the foundation of the world's most experienced hyperthermia program for chronic Lyme disease.

1994

First accidental Lyme response observed

A breast cancer patient's decade of brain fog resolves after whole-body hyperthermia. Dr. Douwes begins investigating the connection between heat and spirochetal death.

1996

Landmark in vitro study published

Collaboration with Prof. Reisinger confirms Borrelia is thermolabile and that antibiotic efficacy increases up to 16-fold at elevated temperatures.

1998–2005

AAT protocol developed and refined

The Antibiotic Augmented Thermoeradication protocol takes shape. International patients begin traveling to Bad Aibling. Co-infection management for Bartonella, Babesia, and Ehrlichia is integrated.

2005–2015

Global recognition

The program expands to treat patients from over 60 countries. Protocols are refined for post-COVID overlap syndromes, ME/CFS, MS patients with underlying Lyme infections, and autoimmune complications triggered by chronic Borrelia.

2015–2024

Precision medicine era

Advanced diagnostics, microbiome restoration, neuroinflammation protocols, and autonomic nervous system treatment are integrated. The program now addresses the full complexity of tick-borne illness across 90+ countries.

12,000+

Patients treated

From six continents. Each one arriving with a story. Each one heard before they were tested, treated before they were billed, and respected before they were discharged.

The legacy continues

A father's work. A son's commitment.

Dr. Friedrich Douwes M.D. passed away in 2022. He left behind a hospital, a protocol, a body of clinical experience unmatched anywhere in the world — and a question that still guides every patient interaction at Klinik St. Georg: What if we listened more carefully?

His legacy continues under his son, Julian Douwes M.D., who serves as Chief Medical Officer of Klinik St. Georg. Alongside Dr. Angelina Svircev M.D. (Lyme Disease Specialist) and the broader clinical team, Julian leads the next generation of the clinic — expanding into neurostimulation, advanced diagnostics, and precision medicine while maintaining the foundation his father built.

The work has evolved. The protocol has been refined hundreds of times. The diagnostic tools are more sophisticated than anything Friedrich Douwes could have imagined in 1994. But the philosophy has never changed: treat the patient, not just the pathogen.

“You put the sun back in my brain.”
— The words of one patient in 1994 that became the north star for thirty years of medical innovation

Medical disclaimer

This article describes the historical development of hyperthermia-based Lyme disease treatment at Klinik St. Georg. Individual patient outcomes vary and past results do not guarantee future outcomes. Whole-body hyperthermia for Lyme disease is considered an investigational therapy in many jurisdictions. This content is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare provider regarding your individual condition. Read our full medical disclaimer.

Continue the journey.

If you have been searching for answers, we would like to hear what you have been through. No commitment. No pressure. Just a conversation.

Whatever you decide, we are here.